Publication Name	World Journal of Cardiology
Manuscript ID	92805
Country	Japan

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Observational Study
Article Title	Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome
Manuscript Source	Unsolicited Manuscript
All Author List	Yasuhiko Saeki, Jun Sawaguchi, Satori Akita, Taka-aki Takamura, Kosuke Fujibayashi, Minoru Wakasa, Hironobu Akao, Michihiko Kitayama, Yasuyuki Kawai and Kouji Kajinami
Funding Agency and Grant Number	Funding Agency Grant Number Vehicle Racing Commemorative Foundation 2013-2015 Grant-in-aid for Scientific Research (C) 18K08051 Grant-in-Aid for Scientific Research (C) 21K08139 Collaborative Research from Kanazawa Medical Univesrity C2015-4
Corresponding Author	Kouji Kajinami, FACP, FAHA, MD, Professor, Department of Cardiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada 9200293, Japan. kajinami@kanazawa-med.ac.jp
Key Words	Lipoprotein (a); Acute coronary syndrome; Percutaneous coronary intervention; Major adverse cardiac events; Prognosis
Core Tip	Two hundred and forty-nine patients with acute coronary syndrome were enrolled in the study. Lipoprotein(a) [Lp(a)] levels were measured before percutaneous coronary intervention (PCI) to 48 h after using an isoform-independent assay. Lp(a) levels decreased significantly from pre-PCI (0 h) to 12 h after, and then increased up to 48 h after. The changes from 0 to 12 h [Lp(a)Δ0-12] were significantly correlated with basal creatinine and Lp(a). Among the tertiles classified according to the changes from 0 to 12 h [Lp(a)Δ0-12], major adverse cardiac events (MACE) were significantly more frequent in the lowest Lp(a)Δ0-12 group than in the other two groups. Multivariate analysis revealed that Lp(a)Δ0-12 and basal creatinine were independent determinants of subsequent MACE.
Citation	Saeki Y, Sawaguchi J, Akita S, Takamura TA, Fujibayashi K, Wakasa M, Akao H, Kitayama M, Kawai Y, Kajinami K. Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome. World J Cardiol 2024; In press

Received	2024-02-06 05:06
Peer-Review Started	2024-02-06 05:06
To Make the First Decision
Return for Revision	2024-04-08 05:49
Revised	2024-04-22 06:39
Second Decision	2024-04-28 02:37
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-04-28 08:36
Articles in Press	2024-04-28 08:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com